Skip to main content
. 2021 Dec 27;14(1):52. doi: 10.3390/pharmaceutics14010052

Figure 2.

Figure 2

(A) Excitation spectrum for pyrene in (FA-Dex-SS)-βCD-(PCL)14 aqueous solutions, (B) plots of fluorescence intensity ratio I337/I333 from pyrene excitation spectra vs. log concentration of (FA-Dex-SS)-βCD-(PCL)14, (C) size distribution for blank (FA-Dex-SS)-βCD-(PCL)14 solution (1 mg/mL) at 90° and 20 °C, (D) size distribution for DOX-SPIO loading (FA-Dex-SS)-βCD-(PCL)14 solution (1 mg/mL) at 90° and 20 °C, (E) TEM micrography of blank (FA-Dex-SS)-βCD-(PCL)14 nanoparticles, and (F) TEM micrography of DOX-SPIO-loading (FA-Dex-SS)-βCD-(PCL)14 nanoparticles.